Cipla bags USFDA approval for generic version of Revlimid; stock surges ~2%

7 Sep 2022 , 02:43 PM

Cipla Limited announced that the United States Food and Drug Administration (USFDA) has granted final approval to its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsule 5 mg, 10 mg, 15 mg, and 25 mg.

Cipla’s Lenalidomide Capsules are an AB-rated generic version of Bristol Myers Squibb’s (Celgene) Revlimid (Lenalidomide) Capsules.

Lenalidomide is an immunomodulatory prescription medicine that is used to treat multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma in adults.

Pregnant women should not use lanalidomide capsules. It is unknown if lenalidomide is both safe and effective in youngsters. Outside of a controlled clinical study, Lenalidomide Capsules should not be used to treat persons with chronic lymphocytic leukaemia (CLL), stated Cipla in its press release.

Revlimid (Lenalidomide) Capsules had US sales of roughly $2.58 billion for the 12-month period ending June 2022, according to IQVIA data.

At around 2.46 PM, Cipla was trading at Rs1,057.65 per piece, up by 1.63% from its previous closing of Rs1,040.70 on the BSE. The scrip touched intraday high and low of Rs1,061.55 and Rs1,035.10 respectively.

For feedback and suggestions, write to us at [e-mail]